Targeting Protein–Protein Interactions in Hematologic Malignancies
Open Access
- 24 January 2025
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pathology: Mechanisms of Disease
- Vol. 20 (1) , 275-301
Abstract
Over the last two decades, there have been extensive efforts to develop small-molecule inhibitors of protein–protein interactions (PPIs) as novel therapeutics for cancer, including hematologic malignancies. Despite the numerous challenges associated with developing PPI inhibitors, a significant number of them have advanced to clinical studies in hematologic patients in recent years. The US Food and Drug Administration approval of the very first PPI inhibitor, venetoclax, demonstrated the real clinical value of blocking protein–protein interfaces. In this review, we discuss the most successful examples of PPI inhibitors that have reached clinical studies in patients with hematologic malignancies. We also describe the challenges of blocking PPIs with small molecules, clinical resistance to such compounds, and the lessons learned from the development of successful PPI inhibitors. Overall, this review highlights the remarkable success and substantial promise of blocking PPIs in hematologic malignancies.Keywords
This publication has 145 references indexed in Scilit:
- Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationOncology and Therapy, 2024
- Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolutionBlood Reviews, 2023
- Targeting the undruggable: menin inhibitors ante portasJournal of Cancer Research and Clinical Oncology, 2023
- Tazemetostat: First ApprovalDrugs, 2020
- Targeting MCL-1 in hematologic malignancies: Rationale and progressBlood Reviews, 2020
- Cell Death Pathways in Lymphoid MalignanciesCurrent Oncology Reports, 2020
- Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesCancer Cell, 2019
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In VivoCancer Cell, 2015
- Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signallingThe Journal of Pathology, 2010
- The road less traveled: modulating signal transduction enzymes by inhibiting their protein–protein interactionsCurrent Opinion in Chemical Biology, 2009